Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Neoadjuvant nivolumab plus ipilimumab in resecteerbare NSCLC (Galaxy 3) (GALAXY 3)

5 november 2026 bijgewerkt door: Shuben Li, The First Affiliated Hospital of Guangzhou Medical University

Neoadjuvant nivolumab plus ipilimumab bij resecteerbare niet-kleincellige longkanker

Neoadjuvant immunotherapy followed by surgery has emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, conventional chemotherapy components may increase treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1 expression <1% remains to be improved. Emerging evidence has demonstrated that the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) provides superior responses in the treatment of advanced NSCLC. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC.

Studie Overzicht

Toestand

Werving

Interventie / Behandeling

Gedetailleerde beschrijving

Lung cancer remains the leading cause of cancer-related death globally. Neoadjuvant immunotherapy followed by surgery has been emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). Numerous clinical trials highlighted the efficacy of preoperative immunochemotherapy, including remarkably shrinking the primary lesion, eliminating micrometastases and ultimately contributing to survival outcomes. Notably, studies also demonstrated neoadjuvant immunochemotherapy increased the access of modified surgery and enhanced survival prognosis of patients with locally advanced NSCLC (IIIB).

Despite these advances, certain limitations remain. Conventional chemotherapy components may elevate treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1<1% remained to be improve. Emerging evidences demonstrated that nivolumab (anti-PD-1) combine with ipilimumab (antiCTLA-4) provided superior response for the treatment of advanced NSCLC patients. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC. The study will enroll 69 eligible participants, with the primary endpoint being pathological complete response (pCR) rate following neoadjuvant therapy.

Studietype

Ingrijpend

Inschrijving (Geschat)

69

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Guangzhou, China, 510120
        • Werving
        • First Affiliated Hospital of Guangzhou Medical University
        • Contact:
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Informed consent must be signed.
  2. At least 18 years of age.
  3. Histologically or cytologically confirmed non-small cell lung cancer (without EGFR, ALK mutation).
  4. Have measurable and clinical stage II-IIIA with no known PD-L1 expression or PD-L1 ≤ 1%.
  5. disease eligible for surgery.
  6. No previous systematic therapy or radiotherapy.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  8. At least one measurable lesion.
  9. No major organ dysfunction, including liver, kidney, and cardiac function.

Exclusion Criteria:

  1. Patients with active autoimmune disease or history of autoimmune disease.
  2. Patients have received other treatment for non-small cell lung cancer or for any other malignancy.
  3. History of allergy to study drug components.
  4. Pregnant or breast-feeding.
  5. Any mental or psychological condition that would prevent the patient from completing the study or understanding the patient information.
  6. Patients who have other malignancies.
  7. History of major surgery or serious injury within the past 3 months.
  8. HIV, HBV, HCV infection or active pulmonary tuberculosis.
  9. Vaccination within 4 weeks prior to the start of the study.
  10. Presence of underlying medical conditions that, in the investigator's judgment, could increase the risk associated with study drug administration or interfere with the assessment of toxicity and adverse events.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Neoadjuvant treatment

Patients with IIA-IIIB NSCLC will received 2-3 cycles of neoadjuvant Nivolumab (3 mg/kg intravenously (i.v.), every 3 week) plus Ipilimumab (1 mg/kg i.v., every 6 week).

Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy.

After the second cycles treatment, contrast-enhanced chest CT will be performed to evaluate the tumor.

This study evaluates the safety and efficacy of neoadjuvant nivolumab plus ipilimumab for IIA-IIIB NSCLC. Based on preliminary trial results, this study proposes a new treatment regimen.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Pathological Complete Response (PCR)
Tijdsspanne: Within 2 weeks after surgery

Pathological complete response is predefined as no residual viable tumor cells in primary tumor and lymph nodes.

Within 2 weeks after surgery

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
3-year Event-Free Survival (3-year EFS)
Tijdsspanne: From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).

The starting point for EFS was the initiation of neoadjuvant treatment. The endpoint for EFS was defined as the date of death, recurrence, progression, or the last follow-up.

From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).
Major Pathological Response (MPR)
Tijdsspanne: Within 2 weeks after surgery

Major pathological response defined as less than 10% of viable tumor cells in primary tumor.

Within 2 weeks after surgery
Safety (Rate of grade 3 and higher grade treatment-related adverse events (TRAEs))
Tijdsspanne: Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)

Adverse events will be evaluated and recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).

Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)
Radiological Response
Tijdsspanne: Between the last dose of neoadjuvant treatment and surgery

Radiographic response will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

Between the last dose of neoadjuvant treatment and surgery
Postoperative complications
Tijdsspanne: After the surgery assess to 90 days

Postoperative complications will be evaluated and recorded after the surgery following Clavien-Dindo grade. The minimum and maximum values were grade I-V, and the higher scores mean a worse outcomes.

After the surgery assess to 90 days
Intraoperative bleeding
Tijdsspanne: Up to approximately 20 weeks

Intraoperative bleeding was assessed and recorded by the surgical team. Blood loss was estimated by measuring suction canister volume and weighing surgical sponges, subtracting irrigation fluid.

Up to approximately 20 weeks
The Quality of Life
Tijdsspanne: From the Day 1 to at least 90 days after surgery

The quality of life will be evaluated and recorded according to the EORTC QLQ-C30. The minimum and maximum values were 0-100, and the higher scores mean a better outcome.

From the Day 1 to at least 90 days after surgery
Duration of surgery
Tijdsspanne: Up to approximately 20 weeks

Duration of surgery is the time spent in surgery.

Up to approximately 20 weeks
Hospital Stay
Tijdsspanne: Up to approximately 20 weeks

Hospital Stay is the length of inpatient time spent in hospital.

Up to approximately 20 weeks
Feasibility (Completion rate of neoadjuvant treatment and surgery)
Tijdsspanne: From date of treatment allocation until surgery, assessed up to 5 months

Propotion of patients who complete neoadjuvant treatment and receive surgery within 42 days after neoadjuvant treatment

From date of treatment allocation until surgery, assessed up to 5 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

19 juni 2025

Primaire voltooiing (Geschat)

31 maart 2030

Studie voltooiing (Geschat)

31 oktober 2030

Studieregistratiedata

Eerst ingediend

30 maart 2025

Eerst ingediend dat voldeed aan de QC-criteria

11 april 2025

Eerst geplaatst (Werkelijk)

15 april 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 november 2026

Laatste update ingediend die voldeed aan QC-criteria

5 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren